PMC:7127386 / 214-678 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"27","span":{"begin":122,"end":133},"obj":"Species"},{"id":"28","span":{"begin":219,"end":229},"obj":"Species"},{"id":"29","span":{"begin":230,"end":238},"obj":"Species"},{"id":"30","span":{"begin":334,"end":344},"obj":"Species"},{"id":"31","span":{"begin":274,"end":284},"obj":"Chemical"},{"id":"32","span":{"begin":286,"end":295},"obj":"Chemical"},{"id":"33","span":{"begin":297,"end":312},"obj":"Chemical"},{"id":"34","span":{"begin":318,"end":325},"obj":"Chemical"},{"id":"41","span":{"begin":354,"end":361},"obj":"CellLine"}],"attributes":[{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"Tax:11118"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"Tax:2697049"},{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"Tax:9606"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Tax:2697049"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:C000606551"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:D061466"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:D004640"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"CVCL:0574"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ons are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respe"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":362,"end":367},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"ons are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respe"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T3","span":{"begin":219,"end":227},"obj":"Disease"},{"id":"T4","span":{"begin":334,"end":342},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"ons are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respe"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":345,"end":350},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T3","span":{"begin":354,"end":367},"obj":"http://purl.obolibrary.org/obo/CLO_0051719"}],"text":"ons are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respe"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":51,"end":60},"obj":"Chemical"},{"id":"T4","span":{"begin":254,"end":263},"obj":"Chemical"},{"id":"T5","span":{"begin":274,"end":284},"obj":"Chemical"},{"id":"T6","span":{"begin":286,"end":295},"obj":"Chemical"},{"id":"T7","span":{"begin":318,"end":325},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_4781"}],"text":"ons are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respe"}

{"project":"LitCovid-sentences","denotations":[{"id":"T4","span":{"begin":25,"end":239},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ons are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respe"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T8","span":{"begin":71,"end":80},"obj":"CHEBI:36357;CHEBI:36357"},{"id":"T9","span":{"begin":122,"end":133},"obj":"NCBITaxon:11118"},{"id":"T10","span":{"begin":134,"end":145},"obj":"GO:0006260"},{"id":"T11","span":{"begin":150,"end":159},"obj":"CHEBI:36357;CHEBI:36357"},{"id":"T12","span":{"begin":219,"end":229},"obj":"SP_7"},{"id":"T13","span":{"begin":274,"end":284},"obj":"DG_28"},{"id":"T14","span":{"begin":286,"end":295},"obj":"DG_23;NCBITaxon:11646"},{"id":"T15","span":{"begin":334,"end":344},"obj":"SP_7"},{"id":"T16","span":{"begin":345,"end":350},"obj":"NCBITaxon:10239"},{"id":"T17","span":{"begin":354,"end":358},"obj":"CL_6"},{"id":"T24338","span":{"begin":71,"end":80},"obj":"CHEBI:36357;CHEBI:36357"},{"id":"T2435","span":{"begin":122,"end":133},"obj":"NCBITaxon:11118"},{"id":"T41112","span":{"begin":134,"end":145},"obj":"GO:0006260"},{"id":"T93186","span":{"begin":150,"end":159},"obj":"CHEBI:36357;CHEBI:36357"},{"id":"T5199","span":{"begin":219,"end":229},"obj":"SP_7"},{"id":"T32162","span":{"begin":274,"end":284},"obj":"DG_28"},{"id":"T17541","span":{"begin":286,"end":295},"obj":"DG_23;NCBITaxon:11646"},{"id":"T621","span":{"begin":334,"end":344},"obj":"SP_7"},{"id":"T88473","span":{"begin":345,"end":350},"obj":"NCBITaxon:10239"},{"id":"T95408","span":{"begin":354,"end":358},"obj":"CL_6"}],"text":"ons are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respe"}